HighTower Advisors’s BeOne Medicines Ltd ONC Stock Holding History

HighTower Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Buy	+907	New	+$267K	﹤0.01%	3333
2025 Q4	–	Sell	-668	Closed	-$228K	–	4039
2025 Q3	$228K	Buy	+668	New	+$203K	﹤0.01%	3262
2020 Q4	–	Sell	-26,875	Closed	-$7.7M	–	2981
2020 Q3	$7.7M	Sell	26,875 -1,482	-5%	-$348K	0.04%	411
2020 Q2	$5.34M	Buy	28,357 +335	+1%	+$54.5K	0.03%	494
2020 Q1	$3.42M	Buy	28,022 +1,939	+7%	+$303K	0.02%	564
2019 Q4	$4.27M	Sell	26,083 -4,118	-14%	-$684K	0.03%	601
2019 Q3	$3.68M	Buy	+30,201	New	+$4.01M	0.02%	681

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's ONC Position: Q2 2026 in Review

HighTower Advisors opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 907 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #3333 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in ONC as recently as Q3 2025.

HighTower Advisors first reported a position in ONC in Q3 2019 and has held it in 7 quarters since. The position peaked at $7.7M in Q3 2020. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

HighTower Advisors held 907 shares of BeOne Medicines Ltd worth $258K as of Q2 2026.
BeOne Medicines Ltd was a new HighTower Advisors position in Q2 2026.
BeOne Medicines Ltd made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3333 holding.
HighTower Advisors first reported a position in BeOne Medicines Ltd in Q3 2019 and has held it in 7 quarters since.
HighTower Advisors's BeOne Medicines Ltd position peaked at $7.7M in Q3 2020.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.